Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection

Turk J Haematol. 2017 Dec 1;34(4):362-364. doi: 10.4274/tjh.2017.0155. Epub 2017 Jul 28.

Authors

Zhuan Bo Luo¹, Ning Xu¹, Xiao Ping Huang¹, Gui Fang Ouyang²

Affiliations

¹ Department of Respiratory Diseases, Ningbo First Hospital, Affiliated Medical School of Ningbo University, Ningbo, China.
² Department of Hematology, Ningbo First Hospital, Affiliated Medical School of Ningbo University, Ningbo, China.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

China
Humans
Imatinib Mesylate / administration & dosage
Imatinib Mesylate / adverse effects*
Imatinib Mesylate / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Lung Diseases, Interstitial / chemically induced*
Lung Diseases, Interstitial / complications*
Lung Diseases, Interstitial / drug therapy
Lung Diseases, Interstitial / microbiology
Male
Middle Aged
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / administration & dosage*
Pyrimidines / therapeutic use*
Tuberculosis / complications
Tuberculosis / drug therapy*
Tuberculosis / microbiology

Substances

Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
nilotinib